Senseonics Holdings, INC 10-Q quarterly reports

Senseonics Holdings, Inc. Q2 2026 filing shows a substantial increase in total revenue and gross profit, driven by US sales growth and the 365-day product, alongside significant investments in R&D and SG&A.

Senseonics Holdings, Inc. has entered into a definitive agreement to acquire certain German assets from Ascensia Diabetes Care Deutschland GmbH, marking a significant step in its European commercialization strategy.

Senseonics Holdings, Inc. reported a significant revenue increase in Q3 2025, driven by U.S. sales and 365-day product demand, even as management acknowledges substantial doubt about its ability to continue as a going concern.

Senseonics Holdings, Inc. reports significant revenue growth and improved gross margins in Q2 2025, bolstered by recent capital raises that alleviate going concern doubts.

Senseonics Holdings, Inc. reports increased revenue for Q1 2025 but acknowledges substantial doubt about its ability to continue as a going concern without additional funding.

Senseonics Holdings reported a net loss for Q3 2024 and acknowledged substantial doubt about its ability to continue as a going concern due to ongoing losses and the need for additional funding.

Senseonics Holdings, Inc. reported a revenue increase in Q2 2024, but also experienced a net loss due to higher operating expenses and other factors.

Senseonics Holdings, Inc. reported a revenue increase in the first quarter of 2024, but also experienced a net loss due to higher operating expenses and changes in fair value of derivatives.